Boston Scientific Corporation
BSX · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $5,065,000 | $5,061,000 | $4,663,000 | $4,561,000 |
| % Growth | 0.1% | 8.5% | 2.2% | – |
| Cost of Goods Sold | $1,523,000 | $1,637,000 | $1,713,000 | $1,890,000 |
| Gross Profit | $3,542,000 | $3,424,000 | $2,950,000 | $2,671,000 |
| % Margin | 69.9% | 67.7% | 63.3% | 58.6% |
| R&D Expenses | $514,000 | $526,000 | $443,000 | $460,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,741,000 | $1,716,000 | $1,597,000 | $1,612,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $237,000 | $363,000 | $14,000 | $10,000 |
| Operating Expenses | $2,492,000 | $2,605,000 | $2,054,000 | $2,082,000 |
| Operating Income | $1,050,000 | $819,000 | $896,000 | $589,000 |
| % Margin | 20.7% | 16.2% | 19.2% | 12.9% |
| Other Income/Exp. Net | -$111,000 | $122,000 | -$91,000 | -$4,000 |
| Pre-Tax Income | $939,000 | $941,000 | $805,000 | $585,000 |
| Tax Expense | $183,000 | $146,000 | $133,000 | $23,000 |
| Net Income | $755,000 | $793,000 | $674,000 | $566,000 |
| % Margin | 14.9% | 15.7% | 14.5% | 12.4% |
| EPS | 0.51 | 0.54 | 0.456 | 0.384 |
| % Growth | -5.6% | 18.3% | 18.9% | – |
| EPS Diluted | 0.5 | 0.53 | 0.451 | 0.38 |
| Weighted Avg Shares Out | 1,481,700 | 1,478,500 | 1,477,200 | 1,474,200 |
| Weighted Avg Shares Out Dil | 1,495,500 | 1,493,300 | 1,493,100 | 1,490,200 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $22,000 |
| Interest Expense | $87,000 | $90,000 | $87,000 | $139,000 |
| Depreciation & Amortization | $0 | $336,000 | $325,000 | $348,000 |
| EBITDA | $1,026,000 | $1,367,000 | $1,217,000 | $1,071,000 |
| % Margin | 20.3% | 27% | 26.1% | 23.5% |